OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CENCOSUD$2190.0058

CENCOSUD.SN

Food Retail & DistributionVerified

CENCOSUD maintains a capital structure with a debt-to-equity ratio of 1.19, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.92, suggesting that its current liabilities exceed its current assets. This is further supported by the negative net cash position after subtracting total debt, which highlights potential liquidity constraints. In terms of profitability, CENCOSUD's return on equity (ROE) of 6.81% and return on assets (ROA) of 2.12% are below the industry median for Food Retail & Distribution. The company's gross profit margin of 29.37% and operating margin of 6.48% also lag behind the sector average, indicating less efficient cost management and operational performance. Geographically, CENCOSUD's revenue is concentrated in its core markets, with no specific segment breakdown provided in the available data. However, the company's exposure to regional economic conditions and consumer spending patterns is a key factor in its revenue stability. The lack of detailed segment data limits the ability to assess geographic diversification. The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current fiscal year. The capital expenditure of -568.38 billion CLP indicates a reduction in investment, which may affect long-term growth potential. The company's free cash flow of 325.34 billion CLP provides some flexibility for reinvestment or shareholder returns. CENCOSUD faces moderate liquidity risk due to its current ratio of 0.92 and negative net cash position. The company's dilution risk is low, as indicated by the risk assessment, and there are no immediate signs of dilution pressure from recent issuance or shelf registration. The absence of strong buy recommendations from analysts suggests a cautious outlook on the company's stock. Recent events, including analyst estimates and price targets, indicate a mixed sentiment among investors. The mean price target of 3,186.00 CLP and median price target of 3,245.00 CLP suggest a potential upside from the current market price of 2,190.00 CLP. However, the lack of strong buy recommendations and the presence of hold ratings highlight the uncertainty in the company's future performance.

30-day price · CENCOSUD-414.24 (-16.3%)
Low$2020.40High$2597.55Close$2122.00As of26 May, 00:00 UTC
Profile
CompanyCENCOSUD.SN
TickerCENCOSUD.SN
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryFood Retail & Distribution
AI analysis

Business. CENCOSUD operates in the Food & Drug Retailing sector, generating revenue primarily through retail operations in food and drug stores.

Classification. CENCOSUD is classified under the Food Retail & Distribution industry within the Consumer Non-Cyclicals economic sector, with a confidence level of 0.92.

CENCOSUD maintains a capital structure with a debt-to-equity ratio of 1.19, indicating a moderate reliance on debt financing. The company's liquidity position is characterized by a current ratio of 0.92, suggesting that its current liabilities exceed its current assets. This is further supported by the negative net cash position after subtracting total debt, which highlights potential liquidity constraints. In terms of profitability, CENCOSUD's return on equity (ROE) of 6.81% and return on assets (ROA) of 2.12% are below the industry median for Food Retail & Distribution. The company's gross profit margin of 29.37% and operating margin of 6.48% also lag behind the sector average, indicating less efficient cost management and operational performance. Geographically, CENCOSUD's revenue is concentrated in its core markets, with no specific segment breakdown provided in the available data. However, the company's exposure to regional economic conditions and consumer spending patterns is a key factor in its revenue stability. The lack of detailed segment data limits the ability to assess geographic diversification. The company's growth trajectory is expected to remain stable, with no significant changes in revenue forecasted for the current fiscal year. The capital expenditure of -568.38 billion CLP indicates a reduction in investment, which may affect long-term growth potential. The company's free cash flow of 325.34 billion CLP provides some flexibility for reinvestment or shareholder returns. CENCOSUD faces moderate liquidity risk due to its current ratio of 0.92 and negative net cash position. The company's dilution risk is low, as indicated by the risk assessment, and there are no immediate signs of dilution pressure from recent issuance or shelf registration. The absence of strong buy recommendations from analysts suggests a cautious outlook on the company's stock. Recent events, including analyst estimates and price targets, indicate a mixed sentiment among investors. The mean price target of 3,186.00 CLP and median price target of 3,245.00 CLP suggest a potential upside from the current market price of 2,190.00 CLP. However, the lack of strong buy recommendations and the presence of hold ratings highlight the uncertainty in the company's future performance.
Key takeaways
  • CENCOSUD's debt-to-equity ratio of 1.19 indicates a moderate reliance on debt financing.
  • The company's ROE of 6.81% and ROA of 2.12% are below the industry median, suggesting less efficient use of equity and assets.
  • The current ratio of 0.92 and negative net cash position highlight potential liquidity constraints.
  • Analysts have a mixed outlook, with a mean price target of 3,186.00 CLP and a median price target of 3,245.00 CLP.
  • The company's capital expenditure of -568.38 billion CLP indicates a reduction in investment, which may affect long-term growth potential.
  • ## RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyCLP
Revenue$16.59T
Gross profit$4.87T
Operating income$1.07T
Net income$314.92B
R&D
SG&A
D&A
SBC
Operating cash flow$1.09T
CapEx-$568.38B
Free cash flow$325.34B
Total assets$14.86T
Total liabilities$10.24T
Total equity$4.62T
Cash & equivalents$248.63B
Long-term debt$5.49T
Valuation
Market price$2190.00
Market cap$6.03T
Enterprise value$11.27T
P/E19.1
Reported non-GAAP P/E
EV/Revenue0.7
EV/Op income10.5
EV/OCF10.3
P/B1.3
P/Tangible book1.3
Tangible book$4.62T
Net cash-$5.24T
Current ratio0.9
Debt/Equity1.2
ROA2.1%
ROE6.8%
Cash conversion3.5%
CapEx/Revenue-3.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricCENCOSUDActivity
Op margin6.5%3.1% medp25 1.2% · p75 6.8%above median
Net margin1.9%2.0% medp25 0.7% · p75 4.1%below median
Gross margin29.4%26.1% medp25 17.2% · p75 32.0%above median
CapEx / revenue-3.4%-2.5% medp25 -4.6% · p75 -1.4%below median
Debt / equity119.0%56.0% medp25 16.8% · p75 121.1%above median
Observations
IR observations
Mean price target3,186.00 CLP
Median price target3,245.00 CLP
High price target3,652.00 CLP
Low price target2,520.00 CLP
Mean recommendation2.77 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count4.00
Hold count8.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate198.79 CLP
Last actual EPS113.00 CLP
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-06 11:06 UTC#4e3159f7
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 15:10 UTCJob: 740375ca